Molecular Partners (OTCMKTS:MLLCF – Get Free Report) is expected to be issuing its results before the market opens on Thursday, October 29th. Analysts expect Molecular Partners to post earnings of ($0.4008) per share for the quarter.
Molecular Partners Stock Performance
MLLCF opened at $4.01 on Tuesday. Molecular Partners has a one year low of $2.25 and a one year high of $4.85. The business’s 50-day simple moving average is $3.96 and its 200-day simple moving average is $3.33.
Molecular Partners Company Profile
Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Schlieren, Switzerland. The company discovers and develops protein therapeutics based on its proprietary DARPin platform, which uses engineered ankyrin repeat proteins to create targeted and potentially multi-specific medicines.
Molecular Partners’ research focuses primarily on oncology, immuno-oncology and other serious diseases in which precisely targeted protein therapies may offer therapeutic advantages.
Further Reading
- Five stocks we like better than Molecular Partners
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
